ArticleBMC cancer2024

TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.

Zhihong Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.